Literature DB >> 19660834

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.

Susan M Landau1, Danielle Harvey, Cindee M Madison, Robert A Koeppe, Eric M Reiman, Norman L Foster, Michael W Weiner, William J Jagust.   

Abstract

The Functional Activities Questionnaire (FAQ) and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) are frequently used indices of cognitive decline in Alzheimer's disease (AD). The goal of this study was to compare FDG-PET and clinical measurements in a large sample of elderly subjects with memory disturbance. We examined relationships between glucose metabolism in FDG-PET regions of interest (FDG-ROIs), and ADAS-cog and FAQ scores in AD and mild cognitive impairment (MCI) patients enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Low glucose metabolism at baseline predicted subsequent ADAS-cog and FAQ decline. In addition, longitudinal glucose metabolism decline was associated with concurrent ADAS-cog and FAQ decline. Finally, a power analysis revealed that FDG-ROI values have greater statistical power than ADAS-cog to detect attenuation of cognitive decline in AD and MCI patients. Glucose metabolism is a sensitive measure of change in cognition and functional ability in AD and MCI, and has value in predicting future cognitive decline.
Copyright © 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19660834      PMCID： PMC2891865          DOI： 10.1016/j.neurobiolaging.2009.07.002

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN： 0197-4580            Impact factor:   4.673


  31 in total

1.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.

Authors:  C R Jack; R C Petersen; Y C Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; S C Waring; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

2.  Longitudinal volumetric MRI change and rate of cognitive decline.

Authors:  D Mungas; D Harvey; B R Reed; W J Jagust; C DeCarli; L Beckett; W J Mack; J H Kramer; M W Weiner; N Schuff; H C Chui
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

3.  FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment.

Authors:  Gaël Chételat; Francis Eustache; Fausto Viader; Vincent De La Sayette; Alice Pélerin; Florence Mézenge; Didier Hannequin; Benoît Dupuy; Jean-Claude Baron; Béatrice Desgranges
Journal:  Neurocase       Date:  2005-02       Impact factor: 0.881

4.  Unified segmentation.

Authors:  John Ashburner; Karl J Friston
Journal:  Neuroimage       Date:  2005-04-01       Impact factor: 6.556

5.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

6.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.

Authors:  S Minoshima; B Giordani; S Berent; K A Frey; N L Foster; D E Kuhl
Journal:  Ann Neurol       Date:  1997-07       Impact factor: 10.422

7.  Measurement of functional activities in older adults in the community.

Authors:  R I Pfeffer; T T Kurosaki; C H Harrah; J M Chance; S Filos
Journal:  J Gerontol       Date:  1982-05

8.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

9.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Authors:  S L Rogers; M R Farlow; R S Doody; R Mohs; L T Friedhoff
Journal:  Neurology       Date:  1998-01       Impact factor: 9.910

10.  A new rating scale for Alzheimer's disease.

Authors:  W G Rosen; R C Mohs; K L Davis
Journal:  Am J Psychiatry       Date:  1984-11       Impact factor: 18.112
View more
  324 in total

1.  The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes.

Authors:  Laurel A Beckett; Danielle J Harvey; Anthony Gamst; Michael Donohue; John Kornak; Hao Zhang; Julie H Kuo
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.

Authors:  William J Jagust; Dan Bandy; Kewei Chen; Norman L Foster; Susan M Landau; Chester A Mathis; Julie C Price; Eric M Reiman; Daniel Skovronsky; Robert A Koeppe
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 3.  The Alzheimer's disease neuroimaging initiative: progress report and future plans.

Authors:  Michael W Weiner; Paul S Aisen; Clifford R Jack; William J Jagust; John Q Trojanowski; Leslie Shaw; Andrew J Saykin; John C Morris; Nigel Cairns; Laurel A Beckett; Arthur Toga; Robert Green; Sarah Walter; Holly Soares; Peter Snyder; Eric Siemers; William Potter; Patricia E Cole; Mark Schmidt
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 4.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

5.  Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Joshua D Grill; Lijie Di; Po H Lu; Cathy Lee; John Ringman; Liana G Apostolova; Nicole Chow; Omid Kohannim; Jeffrey L Cummings; Paul M Thompson; David Elashoff
Journal:  Neurobiol Aging       Date:  2012-04-13       Impact factor: 4.673

Review 6.  Integrating ADNI results into Alzheimer's disease drug development programs.

Authors:  Jeffrey L Cummings
Journal:  Neurobiol Aging       Date:  2010-05-05       Impact factor: 4.673

7.  Empirical derivation of the reference region for computing diagnostic sensitive ¹⁸fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample.

Authors:  Jerod M Rasmussen; Anita Lakatos; Theo G M van Erp; Frithjof Kruggel; David B Keator; James T Fallon; Fabio Macciardi; Steven G Potkin
Journal:  Biochim Biophys Acta       Date:  2011-09-19

8.  Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4.

Authors:  Michael E Belloy; Valerio Napolioni; Summer S Han; Yann Le Guen; Michael D Greicius
Journal:  JAMA Neurol       Date:  2020-07-01       Impact factor: 18.302

9.  Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data.

Authors:  Kan Li; Wenyaw Chan; Rachelle S Doody; Joseph Quinn; Sheng Luo
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

10.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Terry M Therneau; Val J Lowe; David S Knopman; Jeffrey L Gunter; Matthew L Senjem; David T Jones; Kejal Kantarci; Mary M Machulda; Michelle M Mielke; Rosebud O Roberts; Prashanthi Vemuri; Denise A Reyes; Ronald C Petersen
Journal:  Alzheimers Dement       Date:  2016-09-30       Impact factor: 21.566
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.